Is Gilteritinib sold in domestic hospitals?

Gilteritinib (Gilteritinib) is a drug used to treat acute myeloid leukemia (Acute Myeloid Leukemia, AML). It belongs to a class of drugs called "targeted therapies," which are used to treat certain mutated subtypes of the FLT3 gene in patients with AML.

Giritinib is currently on the market in China, but it is not included in medical insurance. If patients need it, they can go to the hospital to buy it at their own expense, but the price is very high, about 35,000 yuan. For specific prices, please consult the local hospital pharmacy.

Foreign original drugs of gilitinib are even more expensive. For example, the price of the Hong Kong version of the original drug is around 90,000 yuan, and the European version of the original drug is as high as more than 200,000 yuan, which is simply unaffordable for ordinary patients. There are already foreign generic drugs of Giritinib on the market, mainly Laos generic drugs. The price is about four to five thousand yuan, which is relatively cheap. In terms of drug ingredients, the ingredients of domestic and foreign original gilitinib drugs are basically the same as those of generic drugs.

Giritinib has achieved remarkable efficacy in clinical trials, especially in AML patients, including newly diagnosed AML patients and relapsed /refractory AML patients. It represents an important advance in the treatment of AML and offers hope for improved patient prognosis and survival.

However, giritinib is not suitable for all AML patients, but is mainly used for specific subtypes with FLT3 gene mutations. Treatment with giritinib should be carried out under the supervision of a physician, and a treatment plan should be developed based on the patient's specific condition and medical guidance. Although it may cause some side effects, gilitinib represents an important advancement in the treatment of AML and provides patients with a new treatment option.

xa0